ImmuneOncia aims to develop immuno-oncology therapeutics

to transform the standard of care in cancer treatment

  • IR/PR
  • Disclosures

Disclosures

Submission Date Disclosure Title Author
2026-09-14 Material Management Information related to Judgment of Investment(Approval for IND Modification) (IMC-002의 제1상 임상시험계획 변경승인) 이뮨온시아
2026-09-14 Material Management Information related to Judgment of Investment(Application for IND Approval for IND Modification) (IMC-002의 제1상 임상시험계획 변경승인신청) 이뮨온시아
2026-08-14 Semi-annual Report (2026.06) 이뮨온시아
2026-07-28 Report on status of specific securities, etc. owned by executives and major shareholders PAIK SOONMYUNG
2026-05-28 Report on status of specific securities, etc. owned by executives and major shareholders PAIK SOONMYUNG
2026-05-27 Report on significant holdings of stocks, etc. (General) 유한양행
2026-05-27 Report on status of specific securities, etc. owned by executives and major shareholders 유한양행
2026-05-21 Post-issuance report 이뮨온시아
2026-05-21 Results of issuance(Self Disclosure) 이뮨온시아
2026-05-15 [Corrected description]Quarterly Report (2026.03) 이뮨온시아
1 2 3 4 5